Literature DB >> 21682963

Chronic lung disease and HIV infection are risk factors for recurrent tuberculosis in a low-incidence setting.

A C Pettit1, L A Kaltenbach, F Maruri, J Cummins, T R Smith, J V Warkentin, M R Griffin, T R Sterling.   

Abstract

SETTING: Programmatic data from the United States on tuberculosis (TB) recurrence are limited.
OBJECTIVES: To determine the TB recurrence rate and to determine if chronic lung disease (CLD) and human immunodeficiency virus (HIV) infection are risk factors for recurrence in this population.
DESIGN: Nested case-control study among TB cases reported to the Tennessee Department of Health between 1 January 2000 and 31 December 2006. Time at risk for recurrence was through 31 December 2007. Multiple imputation accounted for missing data.
RESULTS: Of 1431 TB cases, 20 cases recurred (1.4%, 95%CI 0.9-2.1). Median time at risk for recurrence was 4.5 years (interquartile range 2.7-6.1). Initial and recurrent Mycobacterium tuberculosis isolates were available for genotyping for 15 patients; 12 were consistent with relapse (0.8%, 95%CI 0.4-1.5) and three with re-infection (0.2%, 95%CI 0.04-0.6). HIV infection (OR 5.01, P = 0.04) and CLD (OR 5.28, P = 0.03) were independently associated with recurrent TB, after adjusting for a disease risk score. HIV infection was a risk factor for TB re-infection (P < 0.001).
CONCLUSIONS: In this low-incidence US population, the TB recurrence rate was low, but CLD and HIV were independent risk factors for recurrence. HIV infection was also a risk factor for TB re-infection.

Entities:  

Mesh:

Year:  2011        PMID: 21682963      PMCID: PMC3172045          DOI: 10.5588/ijtld.10.0448

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  33 in total

1.  Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis.

Authors: 
Journal:  Lancet       Date:  1972-05-20       Impact factor: 79.321

2.  HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers.

Authors:  P Sonnenberg; J Murray; J R Glynn; S Shearer; B Kambashi; P Godfrey-Faussett
Journal:  Lancet       Date:  2001-11-17       Impact factor: 79.321

3.  Controlled clinical trial comparing a 6-month and a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Algerian working group/British Medical Research Council cooperative study.

Authors: 
Journal:  Am Rev Respir Dis       Date:  1984-06

4.  USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results.

Authors:  D L Combs; R J O'Brien; L J Geiter
Journal:  Ann Intern Med       Date:  1990-03-15       Impact factor: 25.391

5.  Factors associated with drug resistance in pulmonary tuberculosis.

Authors:  Jasmin Johnson; Anju Kagal; Renu Bharadwaj
Journal:  Indian J Chest Dis Allied Sci       Date:  2003 Apr-Jun

6.  COPD and the risk of tuberculosis--a population-based cohort study.

Authors:  Malin Inghammar; Anders Ekbom; Gunnar Engström; Bengt Ljungberg; Victoria Romanus; Claes-Göran Löfdahl; Arne Egesten
Journal:  PLoS One       Date:  2010-04-13       Impact factor: 3.240

7.  Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council.

Authors: 
Journal:  Am Rev Respir Dis       Date:  1991-04

8.  Short-course chemotherapy in pulmonary tuberculosis. A controlled trial by the British Thoracic and Tuberculosis Association.

Authors: 
Journal:  Lancet       Date:  1975-01-18       Impact factor: 79.321

9.  Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Hong Kong Chest Service/British Medical Research Council.

Authors: 
Journal:  Am Rev Respir Dis       Date:  1987-12

10.  Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use.

Authors:  Richard E Nettles; Dana Mazo; Karla Alwood; Regina Gachuhi; Gina Maltas; Karen Wendel; Wendy Cronin; Nancy Hooper; William Bishai; Timothy R Sterling
Journal:  Clin Infect Dis       Date:  2004-02-17       Impact factor: 9.079

View more
  15 in total

1.  Treatment and recurrence on re-treatment tuberculosis patients: a randomized clinical trial and 7-year perspective cohort study in China.

Authors:  Jian Du; Le Zhang; Yan Ma; X-Y Chen; Q-P Ge; X-Z Tian; Weiwei Gao; Zhongwei Jia
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-12-05       Impact factor: 3.267

2.  Factors associated with recurrent tuberculosis more than 12 months after treatment completion.

Authors:  L Kim; P K Moonan; C M Heilig; R S Yelk Woodruff; J S Kammerer; M B Haddad
Journal:  Int J Tuberc Lung Dis       Date:  2016-01       Impact factor: 2.373

3.  Recurrent tuberculosis in an urban area in China: Relapse or exogenous reinfection?

Authors:  Xin Shen; Chongguang Yang; Jie Wu; Senlin Lin; Xu Gao; Zheyuan Wu; Jiyun Tian; Mingyu Gan; Tao Luo; Lili Wang; Chenlei Yu; Jian Mei; Qichao Pan; Kathryn DeRiemer; ZhengAn Yuan; Qian Gao
Journal:  Tuberculosis (Edinb)       Date:  2017-01-31       Impact factor: 3.131

4.  Exogenous Reinfection as a Cause of Late Recurrent Tuberculosis in the United States.

Authors:  Julia D Interrante; Maryam B Haddad; Lindsay Kim; Neel R Gandhi
Journal:  Ann Am Thorac Soc       Date:  2015-11

5.  Tuberculosis recurrence in a high incidence setting for HIV and tuberculosis in Brazil.

Authors:  Gisela Unis; Andrezza Wolowski Ribeiro; Leonardo Souza Esteves; Fernanda Sá Spies; Pedro Dornelles Picon; Elis Regina Dalla Costa; Maria Lucia Rosa Rossetti
Journal:  BMC Infect Dis       Date:  2014-10-24       Impact factor: 3.090

6.  The double burden of disease among mining workers in Papua, Indonesia: at the crossroads between Old and New health paradigms.

Authors:  Rodrigo Rodriguez-Fernandez; Nawi Ng; Dwidjo Susilo; John Prawira; Michael J Bangs; Rachel M Amiya
Journal:  BMC Public Health       Date:  2016-09-08       Impact factor: 3.295

7.  Tuberculosis recurrence in a priority city in the state of São Paulo, Brazil.

Authors:  Amadeu Antonio Vieira; Danila Torres Leite; Solange Adreoni
Journal:  J Bras Pneumol       Date:  2017 Mar-Apr       Impact factor: 2.624

8.  Recurrent tuberculosis in Finland 1995-2013: a clinical and epidemiological cohort study.

Authors:  Virve Korhonen; Hanna Soini; Tuula Vasankari; Jukka Ollgren; Pieter W Smit; Petri Ruutu
Journal:  BMC Infect Dis       Date:  2017-11-16       Impact factor: 3.090

9.  Tuberculosis recurrence after completion treatment in a European city: reinfection or relapse?

Authors:  Juan-Pablo Millet; Evelyn Shaw; Angels Orcau; Martí Casals; Jose M Miró; Joan A Caylà
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

10.  Predictors of recurrent TB in sputum smear and culture positive adults: a prospective cohort study.

Authors:  Grace Muzanyi; Y Mulumba; Paul Mubiri; Harriet Mayanja; John L Johnson; Ezekiel Mupere
Journal:  Afr Health Sci       Date:  2019-06       Impact factor: 0.927

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.